The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...

US pharma giant Merck & Co (NYSE: MRK) has announced results from STRIDE-10, a Phase III trial of V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine (PCV), ...

Oncotelic Therapeutics (OTCQB: OTLC) has agreed to sell to Mosaic ImmunoEngineering (OTCPK: CPMV) rights to its clinical-stage necroptosis cancer therapies. The firm’s therapeutics work by ...

Shares of US developer of rare neurological drugs Harmony Biosciences (Nasdaq: HRMY) rose more than 10% to $32.30 today, after it announced the acquisition of Epygenix Therapeutics, accelerating ...

The European Medicines Agency’s (EMA) Emergency Task Force (ETF) has recommended updating COVID-19 vaccines to target the new SARS-CoV-2 variant JN.1 for the 2024/2025 vaccination campaign.

A once-weekly insulin product developed by Novo Nordisk (NOV: N) will be reviewed by an advisory panel, convened by the US regulator, on May 24. The update comes around a month after European ...

A full cycle of production of a drug for the treatment of Fabry disease will be launched in Russia this year, reports The Pharma Letter’s local correspondent.

A full cycle of production of a drug for the treatment of Fabry disease will be launched in Russia this year, reports The Pharma Letter’s local correspondent.

Developed by Seagen, now a part of US pharma giant Pfizer (NYSE: PFE), and Denmark’s Genmab (OMX: GEN), Tivdak received accelerated approval for this indication in 2021. The drug is now co-owned by ...

The CNS specialist earlier announced positive top-line results from its potentially pivotal study 008A, evaluating evenamide (30mg bid) in patients with chronic schizophrenia currently being ...

Swiss generic and biosimilar medicines company Sandoz (SWX: SDZ) has reached agreement with US biotech major Amgen (Nasdaq: AMGN) to resolve all patent disputes between the two companies relating ...

Sino-American biotech Innovent Biologics (HKEX: 01801) has appointed a new chief business officer, Samuel Zhang. Innovent is focused on developing, manufacturing and commercializing innovative ...